BSL1 (Biosafety Level 1) is the lowest level of safety in biosafety labs and is used for removing low risk microbes with low health consequences. This is the kind of laboratory where most basic teaching and research is conducted, and tests that don't involve isolation devices are conducted. BSL1 operations usually involve the use of microorganisms with extremely low health risks, which will not cause disease in immunologically healthy adults.
The basic characteristics of BSL1 laboratories include an open experimental environment that does not require special design or building specifications. The biosafety measures it requires are relatively simple, such as regular laboratory clothing, gloves, and good laboratory operation practices. Such a safe and easy-to-manage environment makes BSL1 laboratories an ideal choice for many educational and research institutions to carry out basic microbiology-related experiments.
BSL1 fermentation services have obvious advantages in biosafety levels, and are especially suitable for projects that have basic requirements for safety and compliance but do not require higher levels of protection.
BSL1 fermentation technology has become an important part of scientific research, education and commercial applications due to its operational safety, ease of use and relatively low cost. With the continuous deepening of research on microorganisms and their metabolites, the application areas of BSL1 fermentation continue to expand, bringing rich potential benefits to the market.
BSL1 fermentation services have important application value. With the continuous advancement of technology and the expansion of its application scope, BSL1 fermentation will have broader market potential in the future and better serve all levels of scientific research, education and business. In line with the development trend, Creative BioMart Microbe is committed to innovating BSL1-level fermentation services and providing the society with a full range of biological solutions. Please feel free to contact us for more information.
Our BSL1 conditions allow our fermentation services to create many products from microbial fermentation that pose no risk to human health. Not only are they varied in their range but also have various uses which will give you the diverse option. We are open to inquiries regarding specific product needs and whether we can partner on creating new applications. Here are a few of the most common products that we can develop and their usefulness in different industries:
Enzyme preparations: amylase and protease (common in food and medicine).
Amino acids: lysine, tryptophan, threonine, etc., some are the most needed ingredients in the feed and food manufacturing process.
Vitamins: Some vitamins are converted into us by fermentation of microbial living beings, such as vitamin B group.
Organic acids: like lactic acid and acetic acid, are useful in food preservation and seasoning.
Antibiotics: Some low-risk antibiotics, like growth-enhancing antibiotics in feed additives.
Our main interest is to optimize strains and develop strains as per customer demand. BSL1 strains mainly comprise of microbes with low environmental and human risks: Bacillus, Lactobacillus, Saccharomyces. These strains are used in enzyme formulations, microbial fertilizers, food fermentation and probiotic products. We have systematic genetic engineering strategies and strain screening strategies to improve already existing BSL1-level strains, from improving strain thermal tolerance, pH tolerance and adaptability to environment.
Through experimental research and the establishment of kinetic models, we design fermentation processes that are suitable for different production scales, solve problems that may arise during the scale-up process, and ensure the stability of the fermentation process and the consistency of the product. We use advanced methods such as the combination of computational fluid dynamics and microbial physiological characteristics, online monitoring and control technology, and artificial intelligence data analysis to improve production efficiency and product characteristics. In addition, we also simulate key parameters through environmental simulation and control algorithm software to reduce the risk of performance degradation during scale-up.
We offer turnkey solutions to take the target products out of fermentation broth and turn them into ultra-pure end products. Such as fermentation and separation coupling to decrease product inhibitory action on the fermentative process and increase the yield; extraction and purification of the desired product from the fermentation solution by solid-liquid separation, concentration precipitation, ion exchange, adsorption, distillation and extraction. We take environmental care and are environmentally friendly with organic solvent free extraction process so that the product has no solvent residues and is environmental friendly.
Case Study 1: Mycoprotein production for animal nutrition with BSL1 fungus.
Mycoprotein, produced by Rhizopus microsporus var. oligosporus, a fungus used in Indonesian cuisine, holds untapped potential for animal nutrition. Once deemed Generally Recognized as Safe (GRAS), this BSL1 organism could transform the field. Researchers suggest utilizing sugar cane molasses and corn steep liquor as nutrients. In a study with five 14 L airlift bioreactors, R. microsporus var. oligosporus grew on CSL alone, yielding 38.34 g/L of mycelium and 70.18% crude protein after 96 hours at 25 °C and 0.5 vvm. This scalable and cost-effective process uses CSL, an agro-industrial by-product, to meet the increasing demand for animal protein in feed.
Fig. 1. A sample of corn steep liquor used in the fermentation process. (Furlan, et al., 2024)
Case Study 2: BSL-1 Citrobacter for affordable typhoid vaccine production.
The typhoid virus is caused by Salmonella enterica serovar Typhi and kills 200,000 people every year. This is why Novartis Vaccines Institute for Global Health (NVGH) is bringing to market a conjugate vaccine against the S. Typhi Vi capsular polysaccharide. Scientists have made Vi antigen production in industrial quantities as efficient as possible with Citrobacter 328, an extremely productive, stable strain, on chemically formulated media in fermentation. Citrobacter 328-derived Vi-CRM197 induced strong anti-Vi antibody production in mice and rabbits. Because it's a BSL-1 species, Citrobacter 328 is the perfect host to generate Vi in safe and cost-effective conjugate anti-Typhi vaccines for typhoid-prone populations.
Fig. 2. Typical 4 L fed-batch fermentation run using glycerol as carbon source and relative Vi production. (Rondini, et al., 2012)
Case Study 3: Enhancing isoprenoid production with BSL1 genetic engineering.
Isoprenoids, vital for industries like medicine and cosmetics, are increasingly produced through microbial engineering. Researchers have optimized E. coli to synthesize various isoprenoids by targeting MEP and MVA pathways. Introducing MVA pathway genes from BSL1 organisms into E. coli has not only complied with LMO regulations but also boosted carotenoid production. The new pSCS constructs outperformed the previous pSNA in fed-batch fermentation, enhancing lycopene output and cell productivity. This advancement promises efficient industrial isoprenoid production with preferred genetic combinations in E. coli.
Fig. 3. The pSCS constructs brings an increase in isoprenoid production in E. coli. (Kang, et al., 2024)
A: The microbes in the BSL1 fermentation services are not harmful to people or the environment. We adhere to the highest biosafety and quality control protocols to make sure everything is done safely. We have our laboratories and manufacturing plants constructed and run according to BSL1 safety guidelines, including (but not limited to) aseptic methods, constant environmental surveillance, and employee biosafety training.
A: We have an interprofessional team of microbiologists, bioengineers and chemists that are always testing new strains and fermenting technologies to make products with new functions and better performance. Our artificial biology techniques of gene editing and metabolic pathway engineering enable us to design novel biosynthetic routes to generate new products otherwise impossible to get by traditional means.
References:
Enter your email here to subscribe